Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc (RPRX) reported trailing twelve months (TTM) revenue of $2.44B as of March 2026, which represents a 7.8% increase year-over-year. The company's operating margin has contracted to 89.3% from 94.0% a year ago. In terms of profitability, RPRX generated $827.29M in net income. Valuation-wise, the stock trades at a P/E ratio of 24.5x and a Price-to-Sales (P/S) ratio of 8.3x. The company generated $718.23M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages
